down arrow

Acumen Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00509G2093
USD
2.31
-0.34 (-13.02%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Soleno Therapeutics, Inc.
Phibro Animal Health Corp.
Ovid Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.
Compass Therapeutics, Inc.
Atea Pharmaceuticals, Inc.
Fulcrum Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Inozyme Pharma, Inc.
Third Harmonic Bio, Inc.

Why is Acumen Pharmaceuticals, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Acumen Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Acumen Pharmaceuticals, Inc.
87.4%
-0.13
89.77%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-268.68%
EBIT to Interest (avg)
-31.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
61.05%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.94
EV to EBIT
-0.41
EV to EBITDA
-0.42
EV to Capital Employed
-3.39
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-171.62%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at USD -53.76 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -137.18 %

-2What is not working for the Company
ROCE(HY)

Lowest at -120.5%

Here's what is working for Acumen Pharmaceuticals, Inc.

Net Profit
Higher at USD -53.76 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -137.18 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Footer loading